These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18264033)

  • 1. Ophthalmic azithromycin (AzaSite).
    Med Lett Drugs Ther; 2008 Feb; 50(1279):11-2. PubMed ID: 18264033
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
    Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
    Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
    Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
    J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
    Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
    Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis.
    Luchs J
    Adv Ther; 2008 Sep; 25(9):858-70. PubMed ID: 18781287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
    Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
    Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial conjunctivitis.
    Chung C; Cohen E; Smith J
    Clin Evid; 2002 Jun; (7):574-9. PubMed ID: 12230683
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotic therapy for trachoma.
    Prescrire Int; 2009 Aug; 18(102):176-7. PubMed ID: 19750586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trachoma.
    Fraser-Hurt N; Mabey D
    Clin Evid; 2002 Jun; (7):605-15. PubMed ID: 12230687
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
    Ambroziak AM; Szaflik JP; Hapunik A
    Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis.
    John T; Shah AA
    Ann Ophthalmol (Skokie); 2008; 40(2):68-74. PubMed ID: 19013912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
    Ohnsman C; Ritterband D; O'Brien T; Girgis D; Kabat A
    Curr Med Res Opin; 2007 Sep; 23(9):2241-9. PubMed ID: 17688706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
    Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
    Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
    Bremond-Gignac D; Nezzar H; Bianchi PE; Messaoud R; Lazreg S; Voinea L; Speeg-Schatz C; Hartani D; Kaercher T; Kocyla-Karczmarewicz B; Murta J; Delval L; Renault D; Chiambaretta F;
    Br J Ophthalmol; 2014 Jun; 98(6):739-45. PubMed ID: 24526744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of azithromycin in patients with cystic fibrosis.
    Yousef AA; Jaffe A
    Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: The treatment of acute infectious conjunctivitis with fusidic acid.
    Rietveld RP; ter Riet G
    Br J Gen Pract; 2006 Mar; 56(524):222. PubMed ID: 16536964
    [No Abstract]   [Full Text] [Related]  

  • 19. Allergic contact dermatitis caused by azithromycin in an eye drop.
    Flavia Monteagudo Paz A; Francisco Silvestre Salvador J; Latorre Martínez N; Cuesta Montero L; Toledo Alberola F
    Contact Dermatitis; 2011 May; 64(5):300-1. PubMed ID: 21480922
    [No Abstract]   [Full Text] [Related]  

  • 20. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.